Home › NDC Lookup › Ingredients › Rosuvastatin › 00310-7570-90
⚪image loading
(from DailyMed)

Crestor Rosuvastatin 10 mg Tablet, Film Coated, 90-count — NDC 0310-7570-90 (Billing 00310-7570-90)

by AstraZeneca Pharmaceuticals LP · 90 TABLET, FILM COATED in 1 BOTTLE

This is a package of 90 tablets of Crestor Rosuvastatin 10 mg Tablet, Film Coated from AstraZeneca Pharmaceuticals LP, marketed since May 2022 and currently FDA-listed; retail pharmacies pay about $8.81 per tablet (NADAC). It is this product's only package size.

NDC 00310-7570-90
🏷️ FDA NDC (as labeled) 0310-7570-90 billing pads the labeler segment with a zero
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0310-7570-90 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0310 labeler · 7570 product · 90 package
Package marketed since
May 9, 2022
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
90 EA per package
Barcode (UPC-A, from the NDC)
3 0310757090 3
Medicaid fills, this package
51 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026
⚠️
Other active recalls for Rosuvastatin (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Dec 31, 2025 — Out of specification for dissolution. (AvKARE) · FDA recall D-0292-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0310-7570-90
Product NDC 0310-7570
11-digit billing NDC 00310757090
NCPDP billing unit EA — each (per item)
Application # NDA021366
SPL Set ID ea84b28f-156f-48df-89e4-b94dbe44fa55
Established class (EPC) HMG-CoA Reductase Inhibitor
Mechanism of action Hydroxymethylglutaryl-CoA Reductase Inhibitors
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-05-09
Route ORAL
Dosage form TABLET, FILM COATED
Substance ROSUVASTATIN CALCIUM
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 051784
GCN 19153
HICL code 025009
Ingredient (HICL) Rosuvastatin Calcium
HIC1 code M
Therapeutic class — broad (HIC1) Blood
HIC2 code M4
Therapeutic class — intermediate (HIC2) Affect Blood Lipids/Sugar/Amino Acids
HIC3 code M4D
Therapeutic class — specific (HIC3) Antihyperlipidemic-Hmgcoa Reductase Inhib(Statins)
AHFS code 24:06.08.00
AHFS class Hmg-Coa Reductase Inhibitors
FDB label name CRESTOR 10 MG TABLET
FDB brand name Crestor
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 051784
  • GCN: 19153
  • HICL (First Databank): 025009
  • AHFS class code: 24:06.08.00
Why two NDCs? The FDA registers this code as 0310-7570-90 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00310-7570-90. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name CRESTOR 10 MG TABLET Ingredient Rosuvastatin Calcium
📖 What it is MedlinePlus · NLM

Rosuvastatin is used to reduce the risk of heart attack or stroke decrease the amount of cholesterol (a fat-like substance that can build up and clog blood vessels causing heart attack or stroke or other health conditions) Rosuvastatin is in a class of medications called HMG-CoA reductase inhibitors (statins). It works by slowing how much cholesterol your body makes. This lowers the amount of cholesterol that can build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It lowers cholesterol and triglycerides when diet alone isn’t enough. Some tablet labels also include slowing atherosclerosis and lowering the risk of heart attack and stroke in ad...
  • Take one tablet by mouth once a day, at any time, with or without food. Swallow it whole. If you miss a dose, skip it and take your next one as usual, without doubling up.
  • The most common are headache, nausea, muscle aches, tiredness, constipation and joint pain. Most people tolerate it well. Call your doctor if muscle pain, tenderness or weakness is...
  • Some medicines raise rosuvastatin levels and muscle risk, including cyclosporine, gemfibrozil and many antivirals. Tell me about everything you take. If you use an aluminum and mag...
📖 Read our full Rosuvastatin guide →
1
Nutrient depletion considerations

Rosuvastatin may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Rosuvastatin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $8.811 $793.00 / 90 tablets
Medicaid paysCMS SDUD · 12 mo $16.93 $1,523.97 / 90 tablets
Medicare drug plans payPart D · Q2 2026 $9.04 $813.86 / 90 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jun 2022 Jan 2026 May 2026 Sep 2026 $8.861 $8.811
Flat over the last 13 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00310-7570-90 You're viewing this Main listing 90 TABLET, FILM COATED in 1 BOTTLE 2022-05-09 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Rosuvastatin 10 mg 11788-0131-05 AiPing 500 tablets $0.036 AB Availability likely save 100%
Rosuvastatin Calcium 10 mg 13668-0180-05 Torrent 500 tablets $0.036 AB Availability likely save 100%
Rosuvastatin Calcium 10 mg 13668-0721-05 TORRENT 500 tablets $0.036 AB Availability likely save 100%
Rosuvastatin Calcium 10 mg 16714-0989-01 NorthStar 90 tablets $0.036 AB Availability likely save 100%
Rosuvastatin Calcium 10 mg 24658-0262-45 PURACAP 45 tablets $0.036 AB Availability likely save 100%
Rosuvastatin Calcium 10 mg 27808-0156-01 Cranbury 90 tablets $0.036 AB Availability likely save 100%
Rosuvastatin 10 mg 50228-0117-10 ScieGen 1000 tablets $0.036 AB Availability likely save 100%
Rosuvastatin 10 mg 50268-0709-15 AvPAK 1 tablet $0.036 AB Availability likely save 100%
Rosuvastatin Calcium 10 mg 60687-0245-01 American 1 tablet $0.036 AB Availability likely save 100%
Rosuvastatin Calcium 10 mg 67877-0440-05 Ascend 500 tablets $0.036 AB Availability likely save 100%
Rosuvastatin Calcium 10 mg 72603-0365-01 NorthStar 90 tablets $0.036 AB Availability likely save 100%
Rosuvastatin Calcium 10 mg 82009-0018-10 Quallent 1000 tablets $0.036 AB Availability likely save 100%
Rosuvastatin 10 mg 82009-0189-05 Quallent 500 tablets $0.036 AB Availability likely save 100%
Rosuvastatin 10 mg 16729-0285-15 Accord 90 tablets $0.049 AB FDA listed save 99%
Crestor 10 mgthis 00310-7570-90 AstraZeneca 90 tablets $8.811 AB Availability likely —
Rosuvastatin Calcium 10 mg 00615-8533-39 NCS 30 tablets — AB FDA listed —
Rosuvastatin 10 mg 31722-0883-31 Camber 100 tablets — AB FDA listed —
Rosuvastatin 10 mg 33342-0262-07 Macleods 30 tablets — — FDA listed —
Rosuvastatin Calcium 10 mg 42677-0302-01 Shandong 90 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 42708-0190-30 QPharma, 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-2451-00 A-S 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-4738-00 A-S 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-5188-00 A-S 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-5189-00 A-S 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-5745-00 A-S 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-5746-00 A-S 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-5770-00 A-S 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-5771-00 A-S 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-6637-00 A-S 90 tablets — AB FDA listed —
Rosuvastatin 10 mg 50090-7430-00 A-S 30 tablets — AB FDA listed —
Rosuvastatin 10 mg 50090-7431-00 A-S 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-7486-00 A-S 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-7487-00 A-S 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-7492-00 A-S 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-7493-00 A-S 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-7967-00 A-S 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 50090-7968-00 A-S 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 51407-0154-90 Golden 90 tablets — AB Discontinued —
Rosuvastatin 10 mg 51407-0849-10 Golden 1000 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 51655-0062-52 Northwind 30 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 51655-0256-52 Northwind 30 tablets — AB FDA listed —
Rosuvastatin 10 mg 55154-0158-00 Cardinal 1 tablet — AB FDA listed —
Rosuvastatin calcium 10 mg 55700-0998-30 Quality 30 tablets — AB Discontinued —
Rosuvastatin Calcium 10 mg 57237-0169-05 Rising 500 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 60290-0044-01 Umedica 30 tablets — AB FDA listed —
Rosuvastain Calcium 10 mg 62135-0691-90 Chartwell 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 63187-0864-30 Proficient 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 63629-7157-01 Bryant 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 65862-0294-05 Aurobindo 500 tablets — AB FDA listed —
Rosuvastatin 10 mg 67046-1627-03 Coupler 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 68071-2407-09 NuCare 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 68071-3623-09 NuCare 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 68071-3722-09 NuCare 90 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 68071-5176-09 NuCare 90 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 68462-0262-01 Glenmark 100 tablets — AB FDA listed —
Rosuvastatin 10 mg 68788-4057-02 Preferred 20 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 68788-7086-02 Preferred 20 tablets — AB Discontinued —
Rosuvastatin Calcium 10 mg 68788-8384-02 Preferred 20 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 68788-8775-02 Preferred 20 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 69367-0360-01 Westminster 100 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 69434-0006-02 Zhejiang 90 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 70377-0007-11 Biocon 30 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 70518-4143-02 REMEDYREPACK 90 tablets — AB FDA listed —
Rosuvastatin 10 mg 70518-4303-00 REMEDYREPACK 90 tablets — AB FDA listed —
rosuvstatin 10 mg 70756-0054-12 Lifestar 1000 tablets — — FDA listed —
Rosuvastatin calcium 10 mg 71205-0008-30 Proficient 30 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 71205-0052-30 Proficient 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 71205-0820-30 Proficient 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 71209-0044-04 Cadila 90 tablets — AB FDA listed —
Rosuvastatin 10 mg 71335-0606-01 Bryant 30 tablets — AB Discontinued —
Rosuvastatin Calcium 10 mg 71335-1733-01 Bryant 30 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 71335-1890-01 Bryant 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 71335-2035-01 Bryant 30 tablets — AB FDA listed —
Rosuvastatin 10 mg 71335-2539-01 Bryant 30 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 71335-9640-01 Bryant 30 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 71610-0215-45 Aphena 45 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 71610-0233-15 Aphena 15 tablets — AB FDA listed —
Rosuvastatin 10 mg 71610-0797-15 Aphena 15 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 71610-0801-45 Aphena 45 tablets — AB FDA listed —
Rosuvastatin Calcium 10 mg 72205-0003-05 Novadoz 500 tablets — AB FDA listed —
Rosuvastatin calcium 10 mg 82804-0291-30 Proficient 30 tablets — AB FDA listed —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
On the market since
May 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Rosuvastatin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAstraZeneca Pharmaceuticals LP
Application holderASTRAZENECA UK LTD
FDA applicationNDA021366 (NDA)
Labeler code00310
First marketedMay 2022
Product typeHuman Prescription Drug
Portfolio113 products on file

More NDCs from AstraZeneca Pharmaceuticals LP labeler code 00310

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
51
Units reimbursed last 4 qtrs
53
Gross reimbursed last 4 qtrs
$897.45
Avg / prescription
$17.60
Avg / unit
$16.9330
Latest quarter Q1 2026
13Rx
Medicaid pays / ea
$16.9330
gross reimbursed
vs
NADAC / ea
$8.8111
acquisition cost
=
Spread
+$8.1219
+92% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
100% MCO
Fee-for-service · 0 Rx Managed care · 51 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 53 units · 1.2 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
1.21.2
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 1.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Crestor — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Crestor. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$5.97M
Claims incl. refills
12.7K
Beneficiaries
8.3K
Spend / beneficiary
$715.22
Spend / claim
$470.39
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Rosuvastatin — the ingredient across all brands.

Top reported reactions

Fatigue14,777
Nausea12,436
Dyspnoea11,983
Diarrhoea11,370
Pain10,909
Headache10,159
Myalgia10,128

Age at onset

Neonate34
Infant5
Child20
Adolescent39
Adult15,626
Elderly23,715

Reporter sex

229,716 reports
Male · 47%
Female · 53%
Unknown · 0%

Serious outcomes

Hospitalization71,815
Death13,539
Life-threatening9,746
Disabling7,059
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 20,197 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 00310-7560-90 · AstraZeneca 00310-7580-90 · AstraZeneca →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.